Management of Apixaban (Eliquis) for Transesophageal Echocardiogram (TEE)
You do not need to stop apixaban for a diagnostic TEE, as it is a low-risk procedure that can be safely performed on uninterrupted anticoagulation.
Risk Classification and Management Strategy
TEE is classified as a low bleeding risk procedure that does not require interruption of direct oral anticoagulants (DOACs) like apixaban 1. The evidence strongly supports continuing anticoagulation through diagnostic TEE procedures.
For Diagnostic TEE (Standard Approach):
- Continue apixaban without interruption 1
- At most, you may omit the morning dose on the day of the procedure if desired, though even this is not mandatory 1
- The PAUSE trial demonstrated safety of omitting DOACs for just 1 day before low-risk procedures, but continuation is equally acceptable 1
Key Supporting Evidence:
The British Society of Gastroenterology and European Society of Gastrointestinal Endoscopy guidelines specifically address this, categorizing procedures by bleeding risk 1. TEE falls into the low-risk category where:
- Low-risk procedures: Last DOAC dose taken 2 days before procedure (or simply omit morning dose) 1
- High-risk procedures: Last DOAC dose taken 3 days before procedure 1
The FDA label for Eliquis recommends discontinuation at least 24 hours prior to procedures with low risk of bleeding or where bleeding would be non-critical and easily controlled 2. However, TEE is so low-risk that even this minimal interruption is often unnecessary in clinical practice.
Clinical Context for TEE Specifically:
Multiple studies demonstrate that patients on uninterrupted DOACs (including apixaban) can safely undergo cardiovascular procedures without preceding TEE 3, 4, 5. In fact:
- Over 6,000 patients underwent AF ablation (a much higher-risk procedure than TEE) on uninterrupted DOACs without mandatory TEE screening, with excellent safety outcomes 4
- Thromboembolic event rates were 0.10% in one registry of 970 patients on uninterrupted apixaban and rivaroxaban 3
Important Caveats:
If TEE is for Pre-Cardioversion Evaluation:
The situation differs if the TEE is being performed to rule out left atrial appendage thrombus before cardioversion:
- Current guidelines recommend at least 3 weeks of adequate DOAC treatment before cardioversion without TEE 5
- If the patient has been on therapeutic apixaban for ≥3 weeks with confirmed adherence, TEE may not be necessary at all 5, 6
- However, if anticoagulation duration is <3 weeks or adherence is uncertain, TEE is indicated 6
Renal Function Considerations:
- Patients with CrCl <30 mL/min require special consideration, as apixaban clearance is prolonged 1
- For any patient with rapidly deteriorating renal function, consult hematology before the procedure 1
Resumption After TEE:
- Resume apixaban immediately after the procedure at the regular scheduled time 2
- No bridging anticoagulation is needed 1, 2
Bottom Line:
TEE is a minimally invasive diagnostic procedure with negligible bleeding risk. Continue apixaban through the procedure, or at most omit only the morning dose on the day of TEE. The risk of thromboembolic complications from stopping anticoagulation far outweighs any theoretical bleeding risk from this low-risk diagnostic test 1, 2.